Global pharma cos take Interpol's assistance to combat counterfeit medicines pharmabiz.com An essential part of the programme is to raise public awareness of the dangers of fake drugs, particularly for people buying medicines online.
While referring to the provisions of compulsory licensing, Mr Subramaniam pointed out the requirement of local working and said that once a patent is granted in India, a manufacturing facility could be set up in India.
As Geneva awakes from its summer slumber post-Jeûne genevois (6 September 2012), the following conferences and negotiations are expected to shape the knowledge governance landscape in the second semester of 2012 at WHO, WIPO and WTO. Here is a list of upcoming meeting of relevance to public health, innovation, access and IPs compiled by Thiru Balasubramaniam, the Geneva Representative of Knowledge Ecology International. Check also thiru's blog full of interesting articles: http://keionline.org/blog/thiru
Planet hope - India is the world's largest manufacturer of generic medicines. But a Supreme Court decision could upend the industry, the result of a long legal battle between a giant pharmaceutical company and advocates of generic drugs. What would the consequences be for millions of sick people around the world?
Hannah Moffat brings you inspiring stories on how communities around the world are fighting poverty, illness and empowering children to live in a better world.
Novartis and Bayer are both charging exhorbitant prices for medicines in India as they continue their fight against the country's patent law that puts people over profits in the name of access to affordable medicines. These cases both could have a major impact on MSF's work in the field, as we rely heavily on affordable medicines produced in India to do our work.
Companies are becoming more organised in their approach and the Index leaders are increasingly coming to view access as a strategic issue. Access to medicine has landed in more boardrooms. The 2012 Index finds that more than 60% of companies now have direct board ownership of access to medicine and that more companies are setting meaningful targets. Among the highest-ranked companies, leadership is coming from the very top, and there’s an ever-increasing organisational focus. Dedicated access functions are being established and incentives to deliver access objectives are becoming more common, and are increasingly supported by performance management systems. For instance, Index leader GlaxoSmithKline has, since the last Index report in 2010, established a Developing Countries and Market Access unit as a department dedicated to access, bringing all its businesses in Least Developed Countries under one umbrella, supported by a new lower price/higher volume business model. Notably, the bonus system for managers in this new unit is structured in a fundamentally different way, to reward volume growth rather than profit growth. Three other companies in the top five - Johnson & Johnson, Sanofi and Gilead – as well as Eisai, have also created similar dedicated departments.
Major pharmaceutical companies from India are reporting huge increases in profits generated primarily by increased penetration into the United Sates pharmaceutical market.
In August, India pharmaceutical major, Wockhardt, reported a 95% increase in consolidated net profit. According to Wockhardt, in the most recent quarter sales in the United States and the EU “contributed 71per cent of consolidated revenue."
Similarly India pharmaceutical majors Lupin, Sun Pharma, and Dr. Reddy’s also are reporting massive growth and profits primarily from the U.S. market.
In the last year Dr Reddy’s sales to the U.S. increased 133%. Net profits are up 88% and revenue from US sales were 44% of total sales
For Lupin, in the past year US sales grew 63% . Profits are up 67% and revenue from US sales is 40 % of total sales revenue
Sun Pharma sales in US are up 104% for the year and revenue from sales in the U.S. account for 39 per cent of Sun’s total sales revenue. Sun’s profit after taxes for the last year is 39%
A few days ago, in a courtroom in India, a landmark ruling was made that could impact future legal battles over the sale of generic versions of expensive medications in India. When the Delhi High Court rules that Cipla, the ...
An article on the Trade-Related Aspects of Intellectual Property Rights (TRIPS) from the IP Justice, an international civil liberties organization promoting balanced intellectual property laws and free expression
A World Intellectual Property Organization project aimed at expanding research on diseases occurring predominately in developing countries using IP-protected material has announced its first research agreements.
Patents give their owners exclusive rights to the production, use, or sale of a product. We grant these rights (usually for 20 years) to inventors when their invention is new, useful, and not obvious. These rights can be transferred or shared at the owner's discretion.
The idea is that patents allow their owners to charge higher prices than they could get if everyone was allowed to sell their product. Product development can be an expensive process, so this provides an important economic incentive to develop new useful products. Ultimately, innovation is paid for by those who buy the new product at the elevated price.
There are two major weaknesses to this approach to funding innovation:
Anyone who can't afford the asking price will be unable to access the product, even if the asking price is higher than the actual manufacturing price. Other inventors must pay a premium to use this new product in their research, or may not be allowed to use it at all, so further innovation is hampered or outright blocked.
In a special report in The Lancet, researchers from Queen Mary, University of London (UK) argue that pending cases against India's patent laws threaten public health and misinterpret international intellectual property agreements.
The report, which is published today (Monday), highlights legal challenges by two pharmaceutical companies, Bayer and Novartis, to key provisions of India's Patents Act. Bayer's appeal was heard last week, and the Indian Supreme Court is due to hear Novartis' appeal tomorrow (11th September).
In their report, "India's patent laws under pressure", Peter Roderick, a barrister, and Allyson Pollock, Professor of Public Health Research and Policy, both from the Centre for Primary Care and Public Health at Queen Mary, University of London, say that the Bayer and Novartis cases "are seeking to undermine public health considerations aimed at improving access and therapeutic advantage".
They conclude: "There are many problems facing access to and rational use of medicines in India but the provisions within the country's patent laws, if more extensively and properly applied, should help rather than hinder such access. India's laws and experiences could provide a useful example for low-income and middle-income countries worldwide."
The report outlines the history and details of the two cases, including an analysis of some of the legal background to the actions.